Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449745 | 0.77 | CDK4 (0.37) | CNR2 | |
| SCHEMBL1225367 | 0.75 | GAA (0.42) | ALDH1A1 | |
| SCHEMBL13046538 | 0.73 | TNF (0.56) | MEN1KMT2ATNFALDH1A1PSMB5 | |
| SCHEMBL12668514 | 0.73 | PARP1 (0.48) | PARP1P2RX7TNFGRM2ALDH1A1 | |
| SCHEMBL1895897 | 0.70 | PARP1 (0.48) | PARP1MEN1KMT2AP2RX7GRM2 | |
| SCHEMBL1896689 | 0.70 | PARP1 (0.71) | PARP1MEN1KMT2AP2RX7GRM2 | |
| SCHEMBL3347472 | 0.70 | NPC1 (0.36) | PARP1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL15869662 | 0.68 | PARP1 (0.52) | PARP1P2RX7GRM2CNR2ALDH1A1 | |
| SCHEMBL1590033 | 0.66 | GAA (0.62) | PARP1MEN1KMT2AP2RX7ALDH1A1 | |
| SCHEMBL23102475 | 0.62 | NPSR1 (0.33) | PARP1P2RX7TNFALDH1A1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385939-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-16 | — | — | EP | claimed |
| US-8041551-B1 | Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components | THE MATHWORKS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | claimed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2385939-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8041551-B1 | Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components | THE MATHWORKS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | PARP1 1759/4885MEN1 3230/4885KMT2A 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.